Related Experiment Video
Updated: Dec 22, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Biomarkers of immune checkpoint inhibitor efficacy in cancer
D E Meyers1,2, S Banerji3,4
1Department of Oncology, University of Calgary, Calgary, AB.
Abstract:
Immune checkpoint inhibitor-based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell-mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes.
Insights
Immune checkpoint inhibitors show promise for various cancers, but only a few patients benefit long-term. This study identifies biomarkers to predict which patients will achieve better outcomes with these therapies.
Area of Science:
- Oncology
- Immunology
- Cancer Biomarkers
Background:
- Immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1 are approved for melanoma, renal cell cancer, urothelial cancer, Hodgkin lymphoma, and non-small-cell lung cancer.
- Despite approvals, a small fraction of patients achieve long-term clinical benefits from these immunotherapies.
- Predicting patient response remains a significant challenge in optimizing cancer treatment.
Purpose of the Study:
- To identify and describe biomarkers associated with predicting patient outcomes in response to immune checkpoint inhibitor therapy.
- To elucidate the complex interplay between tumor-induced immune stimulation, T cell responses, and the tumor microenvironment's immune modulation.
- To enhance the precision of patient selection for immune checkpoint inhibitor treatments.
Main Methods:
- Review and analysis of existing literature on biomarkers related to immune checkpoint inhibitor therapy.
- Exploration of the relationship between tumor immunology, T cell-mediated responses, and the tumor microenvironment.
- Identification of key molecular and cellular factors influencing treatment efficacy.
Main Results:
- Specific biomarkers linked to tumor-related immune stimulus have been identified.
- Key aspects of T cell-mediated immune responses correlating with treatment success are described.
- Biomarkers influencing immune modulation within the tumor microenvironment are highlighted.
Conclusions:
- Biomarkers can predict improved patient outcomes for immune checkpoint inhibitor therapies.
- Understanding the complex immune interactions is crucial for patient stratification.
- Further research into these biomarkers may lead to more personalized cancer immunotherapy strategies.
